This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Natus Medical Announces 2012 Second Quarter Financial Results

“I am also pleased to report that the introduction of our first incubator into the U.S. market is attracting a lot of interest. We remain convinced the incubator market will be an area of solid growth for Natus in the years ahead,” said Hawkins.

As of June 30, 2012, the Company had cash, cash equivalents, and short-term investments of $17 million, stockholders' equity of approximately $259 million, and working capital of approximately $111 million. On June 28, the Company borrowed $31 million on its line of credit and used approximately $27 million of its existing cash to fund the Nicolet acquisition. The approximate $58 million purchase consideration will be reported as a deposit on the Company’s June 30, 2012 balance sheet.

Financial Guidance

Natus updated its 2012 financial guidance. For the full year 2012, the Company expects to report revenue of $295 million to $300 million and non-GAAP earnings per share of $0.58 to $0.63. The Company had earlier said that it expected to report revenue of $256 million to $262 million and non-GAAP earnings per share of $0.57 to $0.62 without giving effect to the Nicolet acquisition.

For the third quarter of 2012, the Company expects to report revenue of $80 million to $82 million and non-GAAP earnings per share of $0.12 to $0.14. This compares to revenue of $51.3 million and non-GAAP earnings per share of $0.07 reported in the third quarter of 2011.

For the fourth quarter of 2012, the Company expects to report revenue of $94.5 million to $97.5 million and non-GAAP earnings per share of $0.27 to $0.30. This compares to revenue of $64.1 million and non-GAAP earnings per share of $0.14 reported in the fourth quarter of 2011.

The Company's full year 2012 and quarterly non-GAAP earnings per share guidance exclude the following charges:

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs